| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 88305 |
Level IV - Surgical pathology, gross and microscopic examination |
26,125 |
25,204 |
$1.33M |
| 88175 |
Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer |
36,739 |
36,363 |
$692K |
| 81514 |
|
2,227 |
2,185 |
$451K |
| 87624 |
Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types |
14,621 |
14,493 |
$382K |
| 88307 |
|
3,411 |
3,369 |
$278K |
| 87491 |
Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe |
10,549 |
10,380 |
$261K |
| 87591 |
Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe |
10,565 |
10,395 |
$260K |
| 87801 |
Infectious agent detection by nucleic acid; amplified probe, multiple organisms |
6,882 |
6,755 |
$244K |
| 88342 |
|
5,331 |
5,216 |
$242K |
| 87481 |
|
8,990 |
6,558 |
$237K |
| U0003 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r |
2,284 |
2,240 |
$168K |
| 88341 |
|
956 |
921 |
$115K |
| 87661 |
Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe |
3,855 |
3,708 |
$87K |
| 88304 |
|
2,042 |
2,027 |
$51K |
| 99000 |
|
23,758 |
23,445 |
$32K |
| 88141 |
|
2,125 |
2,122 |
$17K |
| 88312 |
|
277 |
274 |
$8K |
| 88112 |
|
194 |
162 |
$7K |
| 88142 |
|
405 |
405 |
$6K |
| 87637 |
Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV |
41 |
40 |
$6K |
| 88189 |
|
93 |
90 |
$4K |
| U0005 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 |
173 |
170 |
$4K |
| 88173 |
|
38 |
38 |
$858.70 |
| 87635 |
Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe |
12 |
12 |
$496.32 |
| G0145 |
Screening cytopathology, cervical or vaginal (any reporting system), collected in preservative fluid, automated thin layer preparation, with screening by automated system and manual rescreening under physician supervision |
68 |
68 |
$390.00 |
| 88300 |
|
26 |
25 |
$207.58 |